Latest Medicinal Cannabis News

Cann Group’s FY2026 profit was transformed by a one-off A$55.7 million debt-forgiveness gain, while a leaner cost base and new export sales offered more durable progress. The company remains loss-making on a normalised basis and dependent on lender waivers and a future refinancing.

Rua Bioscience delivered a sharp rise in customer revenue and secured a UK agreement expected to generate NZ$10 million over two years. But PwC disclaimed an audit opinion, warning the company may not have enough cash without another capital raise.

ECS Botanics boosted revenue by 10% to $21.4 million in FY26, delivering positive EBITDA and operating cash flow while advancing international market entry and branded product growth.

Rua Bioscience's FY26 results highlight a 71% surge in customer revenue driven by international expansion, yet the company continues to face significant losses and going concern risks.

Rua Bioscience has gained regulatory approval in New Zealand for five new medicinal cannabis products, setting the stage for domestic sales and advancing its strategy to integrate local cannabis genetics.

Cann Group reported its second-ever quarterly operating cash inflow of $0.24 million in Q4 FY2026, edging closer to cash flow break-even. The company expanded exports to the UK and Germany, launched new products, and completed a leadership transition while redeeming convertible notes and securing additional credit.

ECS Botanics plans to introduce two 2g all-in-one vape products under its OzSun brand in mid-August 2026, expanding its higher-margin B2C portfolio with a capital-efficient supply model.

ECS Botanics delivered a fourth consecutive quarter of positive operating cash flow in Q4 FY26, with a full-year turnaround of $5.9 million. The company’s branded B2C revenue surged 31% year-on-year, supported by product launches and European market expansion.

Rua Bioscience has secured its largest export contract, committing to supply New Zealand-grown medical cannabis flower to a major UK distributor, projecting over NZ$10 million in revenue across two years.

Germany’s Hesse State Office has issued new GMP guidance that questions the viability of fragmented medicinal cannabis supply chains, reinforcing ECS Botanics’ integrated manufacturing approach and potentially tightening market supply.

ECS Botanics has commenced commercial sales of Gelonoidz #20, its first Australian-grown Terphogz cultivar, marking a key step in expanding its premium medicinal cannabis portfolio with plans for more cultivars in FY27.

Little Green Pharma (ASX:LGP) has completed its merger with Cannatrek, creating a dominant player in Australia and Europe’s medicinal cannabis market with a majority stake held by former Cannatrek shareholders.